Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma LSE:AMYT London Ordinary Share GB00BDD1LS57 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 21.75p 21.00p 22.50p 22.00p 21.50p 21.75p 191,243 14:00:06
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1.2 -6.7 -4.1 - 45.31

Amryt Pharma (AMYT) Latest News

More Amryt Pharma News
Amryt Pharma Takeover Rumours

Amryt Pharma (AMYT) Share Charts

1 Year Amryt Pharma Chart

1 Year Amryt Pharma Chart

1 Month Amryt Pharma Chart

1 Month Amryt Pharma Chart

Intraday Amryt Pharma Chart

Intraday Amryt Pharma Chart

Amryt Pharma (AMYT) Discussions and Chat

Amryt Pharma Forums and Chat

Date Time Title Posts
24/9/201710:49Amryt Pharma1,670
27/3/201708:19Amryt Pharma108
21/4/201610:07AMYT1
21/4/201610:04Amryt Pharma2

Add a New Thread

Amryt Pharma (AMYT) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Amryt Pharma trades in real-time

Amryt Pharma (AMYT) Top Chat Posts

DateSubject
24/9/2017
09:20
Amryt Pharma Daily Update: Amryt Pharma is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker AMYT. The last closing price for Amryt Pharma was 21.75p.
Amryt Pharma has a 4 week average price of 20.25p and a 12 week average price of 19.75p.
The 1 year high share price is 28.75p while the 1 year low share price is currently 13.75p.
There are currently 208,339,631 shares in issue and the average daily traded volume is 317,017 shares. The market capitalisation of Amryt Pharma is £45,313,869.74.
21/9/2017
17:38
diamondstar1: Hi Paps, I agree with you here. Yes - they probably had enough money to last them till Q3, when the full EASE PhIII results were available. However, what happens in the unlikely event (35% chance in my estimation) that the results from EASE are negative? Amryt would have extreme difficulty raising further funding at that stage. My guess is this - that they will use some of the 15 million Euro as backup reserves, and some of it to strengthen their pipeline. For example, they need to bring their other compound AP102 (for acromegaly/cushing's disease) to Phase III as soon as possible. This is risk diversification - putting their eggs in several baskets. This was seen with Amicus, whereby portfolio diversification prevented their share price from crashing despite Zorblisa failure. Sure, as a private investor, being diluted in not great. But I can rest assured that the board of directors eg, CEO Joe Wiley will feel the impact of share dilution more than I will. Imagine owning 10% of Amryt shares (worth over £4 million) and being diluted by 25%. Overall, my conclusion is this - that Amryt senior management, though not perfect in the way they raised the 15 million euro capital, are doing this in the best interest of Amryt's future as a biopharmaceutical company.
21/9/2017
16:57
greendragon777: I don't know folks am I reading this wrong or is the share price holding up extremely well considering a 25% dilution? If it holds at current levels I will be very happy. With regards to holding off until next year for the placing, the directors will be looked upon as absolute heros if the stock markets took a turn and all companies similar to AMYT get completely locked out of the markets for funding! I think if you take a long term view on AMYT there is so much upside and I wouldn't be trying to trade a 10% or 20% gain here and thee when there is a possible (and looking increasingly likely) uplift in the '00s and maybe even the '000s of percent! :-) A quick remeinder of those words of wisdom from Warren Buffett himself....."The stock market is an efficient place where money is transferred from the impatient to the patient" :-) Hold onto your AMYT shares for dear life folks or forever hold your peace! haha
21/9/2017
15:33
spuddymadrid: Disgusted Papillon with This placement. Why was This not done next year following increase in share price. It is disgusting. Very unfair to small shareholders. Why were We not told about This at AGM. This is a Good company but Very nasty way to treat small shareholders
15/9/2017
13:13
diamondstar1: Good points raised paps about premiums! Yes, I appreciate this point. Here's another one to consider.. First-to-market vs. Second-to-market. For quite a while, Episalvan was projected to be second-to-market, and Zorbrisa first-to-market. Assuming that there was no clinical differentiators between the 2 ie, efficacy & safety similar (which most people would assume as 'base case'), the standard marketing models would suggest that Episalvan should achieve about 1/5th the sales of Zorbrisa. Therefore, if the 'market valuation' of Scioderm was USD$229 million/£168 million (ie, the upfront payment Amicus paid) - then Amryt 'market valuation' should be circa £33.6. In fact, when Amryt share price was 14p, it's market cap was £28 million. When more recently the share price was 20p, the market cap was £40 million. So, in actual fact, market valuation has not departed greatly from the £33.6 million level. However, more recently, when the Zorbrisa demise came, this effectively becomes a 'game-changer' for Amryt/Episalvan. Valuation should be around the level of Scioderm. Yes, we can apply some 'discount factor' or 'reduction in premium', in order to make this valuation more conservative. But suddenly, being potentially first-to-market will make a huge difference for Amryt. Investors and analysts will hopefully wake up to this fact.
25/7/2017
13:28
greendragon777: I agree Papillon, volume too light really for it to create a good support level at where it jumped to. That said, it's still good news and I think bodes well for the long term on it anyway. Increases the chances of it being adopted etc which will translate into solid sales at some point down the road. Shall we have a crack at some of the headlines after the interim results are announced in September?.....just for the craic like! :-) "Lojuxta returns much higher sales in the first half of 2017 for Amryt than original estimates" "Sales of Lojuxta set to double within 12 months" "Amyrt's share price soars as investors pile in on very positive outlook for the company" "Papillon turns extremely bullish after new share price target is literally off the charts" The question now is......what do we all do here until mid September? hahaha
03/7/2017
15:49
papillon: An example of what bad news can do to a share price is UJO today. The share price has been quite bullish, on good volume, over the last few days, in anticipation of a good result from a N. Lincclnshire planning application, but bad news has just been issued and the UJO share price has collapsed! Confirmation, if any was needed, that news drives share prices.
01/3/2017
11:37
gnnmartin: papillon, I've long ben intrigued by strange reported trades: trades of 1 share being the obvious example. Having read Flash Boys, I wonder if it is automatic trading software, though I don't really expect bots to be interested in small cap shares: at least, the bots that Flash Boys talks about were (IIUC) only interested in shares that trade in five figure dollar amounts. The starting point for designing a bot program is much like chart based trading: look at the recent trades and decide which way the share price is going to move, but whereas the chartist is interested in movement over the next days to months the bot is interested in movement over the next seconds to minutes. In the case of Flash Boys, the bot is interested in the movement over the next few microseconds. However, pseudo charting is just the starting point. Much like the game of 'paper, scissors, stone', or indeed like poker, the bot hopes to work out what other traders intend to do by studying what they have recently done. Naturally, bots will then take steps to ensure that other bots (and human traders) don't twig what the bot intends, or even are positively misled as to the bots intentions. Humans can do the same: as did that guy from London who made millions trading on Nasdaq and has just lost his fight to avoid extradition to the USA where he faces charges of distorting the market. The moral is that it is dangerous to make too much money on the USA market even if you are only using the same trading techniques as the big boys are using in the USA. In the USA (metaphorically speaking) poker games often end in gun fights. So, why the single share trades? Obviously this has to be done by a bot (or person) that pays millipence per trade, which rules out me! But I guess that there are some bots that look at the number of trades in the last hour (say), or look at the average price of the last 5 deals (again, I'm trying to imagine something fairly believable, nothing more accurate than that). In this case the bot that is placing the single share trades reckons that some other bot or bots might be interested in that security and wants to 'paint a picture' (as Tom Wolfe put it, in Bonfire of the Vanities). The pictures are not necessarily only aimed at other bots. People tend to look at closing prices and the movement reported during the day, or at some automatic report of closing/opening/current price, and the various media use different ways of reporting. You have probably noticed that ADVFN, LSE, III, and other can sometimes report quite different data for closing prices, current movement, and so forth. A bot that posts 5 trades of one share might be aimed at influencing one or more of these data channels. It's a bit like the ways that city boys nudged the LIBOR (etc.) rates by reporting phoney interest in loans. As ever, the line between clever negotiating and dishonest trading is blurred, and the clever negotiator who is too successful is liable to find him (or her) self described as dishonest. One oddity that blossomed recently is the reported trade that is deleted and then immediately re-instated. For example, a trade of £10,000 at 10p per share might be deleted and immediately re-instated some hours or even a day later, by which time 10p lies well outside the current quoted spread. The honest reason for deleting and reinstating a trade is that you failed to mention that there were bargain conditions attached (say), or you got the bargain price wrong, or the quantity, or such like, but in almost all, perhaps all, examples I have noticed, the trade deleted is then reposted without any change. I notice that some media channels report the number of shares traded and fail to count a deleted trade as positive. If (for example) 100,000 shares are reported as traded at 10p at 8:00, and then at 12:00 it is reported that at 8:00 100,000 shares were wrongly marked as traded at 10p, and then at 12:01 it is reported that at 8:00 100,000 shares were traded at 10p, then some data streams add 300,000 shares to their tally of trades during the day, giving a false impression of trading activity. I expect too that some people (or bots) will get a false impression of the current share price when a big trade is posted at what is in effect an old price. I could go on, but I guess that is more than enough for something fairly off thread. All guesswork.
04/11/2016
16:22
papillon: It's proving to be a very slow death for the AMYT share price in the continuing absence of good news (in fact any news!) from the company. I seem to remember the intraday low was around 14-14.25p back in early July. Will a retest of that low encourage bottom fishing buyers again, or will the AMYT share price continue it's descent into oblivion? Answers on a postcard please! LOL. Is AMYT worth a bottom fishing buy I wonder when it's below 15p?
19/8/2016
19:29
papillon: dingo75 16 Aug'16 - 13:26 - 295 of 302 1 0 papp lol egg on your FACE! >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> LOL. I'm always ending up with egg on my face, dingo75. However I still believe we will see a small, short term, fall back in the AMYT share price and then the formation of a bullish Inverse Head & Shoulders. You could be right and I will be proved wrong and end up with egg on my face, but I'm hopeful I will soon be proved right. After all a bullish chart formation, after a period of a falling share price, is often the sign that a significant price reversal and subsequent major share price rise is on the cards. Don't throw any more raw eggs at me just yet, dingo75, but keep them ready! LOL.
01/5/2016
21:27
papillon: Amryt Pharmaceuticals is worth a closer look By Gary Newman | Sunday 1 May 2016 Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article. As usual I had a great day at the UK Investor Show, especially listening to many of the informative speakers on the main stage. When it came to the companies exhibiting, to be honest there are many of them which I wouldn’t dream of putting my money into – either because I view them as poorly run or vastly over-valued at their current share prices. But there were also some that look to have good potential for the future, as well as offering value, and are definitely on my watch list, and amongst them was recently listed Amryt Pharmaceuticals (AMYT) which completed a reverse takeover into Fastnet Equity and was admitted to trading a couple of weeks ago. I previously covered this company as a buy at 2.9p one weekend back in late February, but it was then suspended before open on the Monday morning when news of the deal was confirmed, and you can now get in even cheaper as the opening day price of 24p (equivalent to 3p prior to the deal) has subsequently dropped to under 20p to buy. It is still early days and like any similar stage pharmaceutical company it does carry a fair amount of risk, but unlike many of the AIM listed ones it does at least have a product, Episalvan, that is already approved in the EU, Norway and Iceland, and also has further potential for development to treat other diseases. Amryt has a very short history as it was only formed in August of last year, but that came about via the acquisitions of German bio-tech Birken AG and Swiss pharmaceuticals company Sompharmaceuticals SA. It also has a team behind it that have a good track record in the industry, with chairman Harry Stratford having previously built two successful listed pharma companies (including Shire which is now FTSE100 listed), and CEO Joe Wiley and CFO/COO Rory Nealon who have years of experience in life sciences. Its licenced product Episalvan is used to treat partial-thickness wounds in adults, but the company is looking to extend that to epidermolysis bullosa, which commonly occurs in children, and is expecting to begin phase three trials in the second half of this year. The company currently has orphan status in both the US and EU for this potential EB treatment, meaning that not only will it get tax breaks but also an exclusivity period to develop a cure for this condition. The only downside with that is that orphan drugs tend to be less profitable than those that cure common illnesses, but can still be very lucrative and the global EB market is estimated at $1.5 billion per annum, so the company won’t even need a big slice of that to succeed. Amryt also has the Imlan brand (developed by Birken) which is on sale and is used by people suffering from dry skin and other dermatitis conditions. There are also a couple of other drugs, but they are yet to undergo clinical trials and are too early a stage to really be that relevant at the moment, although that could well change in the future. In terms of the financials it is very hard to get a real grip on these as there isn’t a lot to go on by way of figures, other than that the company raised a gross amount of £10 million at 24p when it listed in April, and prior to that it also had close to £10 million in the bank. The total amount paid for the takeover of Amryt was just under £30 million in shares and was settled by the issue of 123 million shares (circa 59%) in the new company, with those who originally sold Birken receiving 30 million of those, and 12 million going to former Som owners. Since relisting it should have paid Birken €10 million as a milestone payment for the Episalvan EU approval, with potentially a further €40 million to pay in the future, plus royalties on this product of 6-9% of sales for a ten year period. For a company of this size there is a relatively small freefloat, with over 62% of shares not in public hands, and the Software AG-Stiftung fund owning 20.9%, and previously having funded Birken to the tune of around €54 million to develop its products. There is too much to go into every detail, so I would suggest that anyone interested in investing reads the admission document before doing so, and also realises that this does still have risks attached if it is going to justify its current market cap of £42 million. But I think the current share price, or possibly even slightly lower if you get he chance, offers a good buying opportunity as I think many people piled into this one expecting fireworks overnight. But typically of many PIs, when that didn’t happen they have gradually got bored and sold to chase riches elsewhere, and that has dragged the share price down to where it is. That unfortunately is also one of the disadvantages of a small freefloat as it doesn’t take a lot of selling to have a disproportionate affect on the share price, but that also works the other way at times when the shares are in high demand, such as after good news. So for me overall this is a speculative buy at these levels, especially given how far along the road it is with its products compared to many similar sized pharmas. Just be aware that it will need to raise further funding in the future, although that might not need to be via equity issue given previous funding from the biggest shareholder. - See more at: HTTP://www.shareprophets.com/views/20422/amryt-pharmaceuticals-is-worth-a-closer-look#sthash.2A4X4B41.dpuf
Amryt Pharma share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20170924 16:01:01